Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/42/79/86/427986d7-43ae-db57-604e-2cb279213fac/mza_7407224300728278017.jpg/600x600bb.jpg
Dangerous Ideas In Drug Development
NSW Early Phase Clinical Trials Alliance (NECTA)
19 episodes
2 days ago
Join our hosts from the NSW Early Phase Clinical Trials Alliance as they interview guests from across the early drug development industry. We'll be discussing the latest novel agents that are breaking ground in oncology around the world.
Show more...
Medicine
Health & Fitness
RSS
All content for Dangerous Ideas In Drug Development is the property of NSW Early Phase Clinical Trials Alliance (NECTA) and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join our hosts from the NSW Early Phase Clinical Trials Alliance as they interview guests from across the early drug development industry. We'll be discussing the latest novel agents that are breaking ground in oncology around the world.
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38424943/38424943-1689065278050-30e218f9af614.jpg
NECTA Dangerous Ideas in Drug Development - Immunocore
Dangerous Ideas In Drug Development
43 minutes 2 seconds
2 years ago
NECTA Dangerous Ideas in Drug Development - Immunocore

This week we chat with a guest from Immunocore who specialise in soluble T-cell receptor technology. We'll be diving into their work with KIMMTRAK in uveal melanoma, as well as exciting upcoming studies with PRAME and PIWIL1 across multiple cancer types.

Dangerous Ideas In Drug Development
Join our hosts from the NSW Early Phase Clinical Trials Alliance as they interview guests from across the early drug development industry. We'll be discussing the latest novel agents that are breaking ground in oncology around the world.